Contact Us
Chengguan District, Lanzhou, Gansu, China
© 2025 Jeifer Pharmaceutical, All Right
Reserved.
Egg Yolk Carbon Lipid (For Injection) BP EP USP Pharma Grade acts as a vital raw material in several pharmaceutical manufacturing processes. Industries draw on its natural origins for injectable emulsions, using the lipid-rich base as a stable, safe vehicle for delivering essential compounds directly into the body. This pharmaceutical-grade substance is processed from hen egg yolks under rigorous conditions, creating a carbon lipid component that meets global pharmacopoeias like BP, EP, and USP standards. Its tight specifications bring confidence to manufacturers and health professionals looking for high purity and quality in parenteral nutrition and drug delivery.
On a molecular level, Egg Yolk Carbon Lipid consists mainly of phospholipids—including phosphatidylcholine, phosphatidylethanolamine, and sphingomyelin—alongside small quantities of cholesterol and trace carbohydrates. These natural molecules create the amphiphilic structure needed to support stable emulsification in aqueous solutions. The average molecular formula for the primary components hovers around C42H80NO8P for lecithin-type lipids, though natural variability exists. Typical density values range from 1.01 to 1.07 g/cm3 due to the tight packaging of glycerophospholipids and fatty acid chains. Its complex yet uniform molecular architecture ensures high performance in medicinal solutions, allowing for reliable mixing, dispersion, and bioavailability.
The substance appears in various physical forms depending on manufacturer and concentration processes, including fine powder, waxy solid flakes, small pearls, or rich yellowish liquid. Each form supports different application requirements. In its most stable pharmaceutical presentation, it demonstrates a slightly granular or powdery structure, providing ease of dissolution and blending during formulation of injectables. When solubilized, it produces a milky white, opaque emulsion. These emulsions exhibit strong resistance to phase separation, giving pharmacists assurance in the product’s consistency and predictability during storage and administration. The specific combination of surface-active molecular groups grants superior dispersibility and chemical compatibility in multi-component mixtures.
Strict specifications define Egg Yolk Carbon Lipid for injectable use. Heavy metal content remains below pharmacopeia thresholds, often under 1 ppm for lead and cadmium. Microbial load sits at levels fit for parenteral application, with sterility validated for pharmaceutical use. Peroxide and acid values fall within industry standards to assure stability and reduce risk of oxidative degradation. Purity measures go beyond 99% for primary phospholipid fractions. Compatibility with other parenteral components, including fat-soluble vitamins and chemotherapeutic agents, adds another layer of value and function.
Egg Yolk Carbon Lipid (For Injection) meets regulatory and customs requirements across major markets. Its international HS Code typically falls under 2923.20.00, grouped alongside other organic phospholipids and chemically-defined compounds. Regulatory frameworks from the U.S. Food and Drug Administration, European Medicines Agency, and other authorities specify quality, origin, and documentation requirements, demanding robust certificates of analysis and traceability to assure compliance.
Manufacturers treat Egg Yolk Carbon Lipid as a low-hazard material under most workplace safety norms. Safety Data Sheets classify this substance as non-carcinogenic and free of mutagenic risk when handled properly in GMP-compliant facilities. Though categorized as non-hazardous for transport, caution applies in preventing microbial contamination or oxidation, as these events could risk patient safety or product integrity. Proper handling during weighing, mixing, and storage means staff use gloves, gowns, masks, and closed handling systems. Storage conditions should exclude light and heat while maintaining low humidity to preserve chemical stability and pharmacological efficacy.
Egg Yolk Carbon Lipid’s significance lies in its multifaceted pharmaceutical uses. Its broad utility as a key raw material includes total parenteral nutrition, encapsulation of active pharmaceutical ingredients (APIs), and formulation of long-acting injectables. Multi-liter solutions are prepared by dispersing powder, flakes, or pearls in sterile, isotonic water to create nano- or microemulsions. These emulsions allow transport of lipophilic vitamins, hormones, or cytostatic drugs, dramatically improving their absorption in the bloodstream. Its natural biocompatibility stands out, as the body easily metabolizes and incorporates its lipid fractions without provoking allergic or inflammatory responses. Both its amphiphilic and stabilizing properties boost its appeal for pharmaceutical technologists seeking safe, effective emulsifiers that maintain reproducibility batch after batch.
Extraction from fresh, high-quality hen eggs under GMP standards supports consistent quality. Processing plants trim variability by relying on monitored supply chains and in-process controls that maintain lipid profiles, clean away contaminants, and check for forbidden residues. Scaling up production while meeting global demand creates challenges, especially in maintaining the delicate balance between purity, activity, and chemical integrity. Manufacturers must continually optimize extraction, drying, and homogenization steps to offer repeatable performance to pharmaceutical end-users.
Egg Yolk Carbon Lipid fills a vital gap in modern healthcare by making parenteral nutrition and injectable formulations possible for vulnerable patients—premature infants, cancer patients, and those with severe digestive issues benefit most directly. Continued advancements could focus on refining purification technology to minimize residual protein or cholesterol content and bring down immunologic risks even further. Ensuring uninterrupted supply chains means building robust networks among egg producers, extraction facilities, and end-product manufacturers, backed by transparent traceability and fair-trade practices. Ongoing investment in quality control and collaborative development programs may drive even safer, more effective pharmaceutical lipids that serve tomorrow’s healthcare needs.
Chengguan District, Lanzhou, Gansu, China
